Core Viewpoint - Karolinska Development AB is initiating a rights issue to raise approximately SEK 202.6 million for the continued development of existing investments and general corporate purposes [2][6]. Rights Issue Details - The rights issue involves a maximum of 675,193,985 series B shares at a subscription price of SEK 0.30 per share [6]. - The subscription period runs from January 13, 2026, to January 27, 2026, with trading in subscription rights occurring from January 13 to January 22, 2026 [4][6]. - Shareholders holding series A and B shares will have preferential rights to subscribe, with one existing share granting five subscription rights, and two subscription rights allowing the purchase of one new series B share [6]. Financial Commitments - Prior to the rights issue, the company has secured subscription undertakings from its Board of Directors and management amounting to approximately SEK 5.2 million, representing about 2.6% of the rights issue [6]. - Additionally, the company has entered into guarantee commitments totaling approximately SEK 95.2 million, which is about 47% of the rights issue, including the subscription undertakings [6]. Timeline and Trading Information - The estimated date for announcing the outcome of the rights issue is around January 29, 2026, with trading in new shares expected to commence on February 16, 2026 [4][6]. - Trading in paid subscribed shares (BTA) will occur from January 13, 2026, until around February 12, 2026 [4]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors, to enhance the chances of success in advancing medical innovations [11]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].

Core Viewpoint - Karolinska Development AB is conducting a rights issue of series B shares amounting to approximately SEK 202.6 million, which has been approved by the Board of Directors and the extraordinary general meeting [2]. Group 1: Rights Issue Details - The rights issue is set to raise approximately SEK 202.6 million before transaction costs, as resolved by the Board on December 1, 2025, and approved on January 8, 2026 [2]. - An information document has been prepared in accordance with the Prospectus Regulation, detailing the terms and conditions of the rights issue, which has been registered with the Swedish Financial Supervisory Authority [3]. - The timetable for the rights issue includes trading in subscription rights from January 13 to January 22, 2026, and a subscription period from January 13 to January 27, 2026 [4]. Group 2: Advisory and Legal Support - Redeye AB is acting as the financial adviser, while Cirio Advokatbyrå AB serves as the legal adviser for the rights issue [5]. Group 3: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [7]. - The company aims to create and grow companies that advance medical innovations into commercial products, benefiting patients and providing returns to shareholders [8]. - Karolinska Development has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around top scientists supported by experienced management teams [9].

Core Viewpoint - Karolinska Development AB held an Extraordinary General Meeting on January 8, 2026, where significant resolutions were made regarding share capital increase and company name change [1]. Group 1: Share Capital Increase - The Board of Directors' resolution to issue new shares with preferential rights for existing shareholders was approved, allowing an increase in share capital by up to SEK 6,751,939.85 through a rights issue of no more than 675,193,985 shares of series B [2]. - Each existing share entitles shareholders to five subscription rights, with two subscription rights allowing the subscription of one new share of series B at a price of SEK 0.30 per share [3]. Group 2: Subscription Period - The subscription period for the rights issue is set from January 13, 2026, to January 27, 2026 [4]. Group 3: Amendments to Articles of Association - The company name will be changed to KDventures AB, and amendments were made to the object of the Company's business, with share capital limits set between SEK 2,650,000 and SEK 10,600,000, and the number of shares limited to between 265,000,000 and 1,060,000,000 [5]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [8]. - The company has access to world-class medical innovations from leading universities and research institutes, aiming to build companies around leading scientists supported by experienced management teams [9]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, led by a team of investment professionals with a strong track record [10].

STOCKHOLM, SWEDEN – May 15, 2025. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 15, 2025. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the choice to exercise their voting rights at the AGM by attending in person, by postal voting or through a proxy. The following resolutions were passed by the shareh ...